Testing effectiveness (Phase 2)WithdrawnNCT04029038
What this trial is testing
Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma
Who this might be right for
CD19 PositiveCD22 PositiveMinimal Residual Disease+7 more
M.D. Anderson Cancer Center